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It �as been well known t�at radiation t�erapy �RT�� 
is one of t�e major effective treatments for nasop�a-
ryngeal carcinoma. However�� due to t�e �ig� dose of 
radiation�� patients frequently suffer from toxic effects�� 
suc� as xerostomia�� �earing loss�� �ypomnesia�� dys-
p�agia [1]�� neck stiffness [�]�� and nasal synec�ia [3]. 
T�ere is an urgent need for novel approac�es to im-
proving response of cancer cells to radiation t�erapy. 
Unfortunately�� effective non-toxic radiosensitizers for 
clinical use are �ard to find.
Arsenic trioxide �ATO�� �as been reported as an ef-
fective agent in t�e treatment of patients wit� leukemia 
[��6]. Recently�� several studies �ave been focused on 
t�e antitumor effects of ATO on solid tumors [���11]. 
It �as been reported t�at ATO en�anced radiation 
response in glioma [��� �]�� cervical cancer [1�]�� �ead 
and neck squamous cell carcinomas [11]. In our 
previous studies�� we demonstrated several potential 
mec�anisms by w�ic� ATO reduced t�e invasive and 
metastatic properties of nasop�aryngeal carcinoma 
cells�� including G�/� arrest�� up-regulation of p�3 
and Bax expression�� and down-regulation of Bcl-� 
expression [1��� 13]. In addition�� we found t�at ATO 
en�anced radiosensitivity of nasop�aryngeal carci-
noma cells in vitro [13]. T�us�� it is reasonable to de-
termine w�et�er ATO can increase radiation response 
of nasop�aryngeal carcinoma in vivo. T�e aims of our 
present study are to determine t�e t�erapeutic effects 
of ATO�� RT�� and combination of t�e bot� treatments on 
nasop�aryngeal carcinoma in vivo�� to detect t�e toxic 
effects of t�e combined treatment�� if any�� and to evalu-
ate t�e potential benefits for future clinical use. 
MATERIALS AND METHODS
Test compound and reagents. ATO was pur-
c�ased from Harbin-Eda P�armaceutical Co. Ltd�� C�i-
na. Ot�er reagents are t�e �ig�est grade available.
Animal model and treatment. BALB/C mice�� 
���� weeks of age and weig�ing 1���� g�� were ob-
tained from t�e Experimental Animal Center of Sun 
Yat-Sen �edical University �Guang Z�ou�� C�ina��. T�e 
current study was approved by t�e Et�ic Committee 
of Cancer Hospital�� S�antou University.
T�e mice were raised under SPF �specific pat�ogen 
free�� condition. Human nasop�aryngeal carcinoma 
cell line�� CSNET-1�� was used in t�e experiment. It is a 
poorly differentiated squamous cell carcinoma�� usually 
maintained in a frozen state�� and �as been proven to be 
transplantable in severe combined immunodeficiency 
�SCID�� mice [1�]. Before experiment�� 1�6 exponentially 
growing cancer cells were inoculated subcutaneously 
into t�e back of several Balb/c nude mice. W�en tumors 
reac� approximately � mm in lengt� diameter�� t�ey were 
obtained by surgical resection�� minced wit� scissors 
into fragments of about 1 mm in diameter and t�en 
implanted subcutaneously into t�e armpit of BALB/C 
mice. W�en tumors were palpable �~ � mm in lengt� 
diameter���� mice were randomly divided into several 
groups: one untreated control�� t�ree groups treated wit� 
radiation alone �RT���� one ATO alone �ATO���� and t�ree 
groups wit� ATO plus radiation �ATO + RT��. RT and ATO + 
RT groups were treated wit� single radiation of ��� ��� and 
6 Gy�� respectively. T�ere were � mice in eac� group.
ATO �� mg/kg per day�� was administered i. p. for 
6 days. In t�e combined treratment�� after t�e last ATO 
treatment�� local irradiation of ��� � or 6 Gy was delivered 
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wit� an X-ray mac�ine �Tape 1T1-V�� Beijing�� C�ina���� ope-
rating at 1�� KV�� 1� mA�� �.� mm Cu-equivalent filter�� 
wit� a dose rate of 1���.3cGy/min. During irradiation�� 
unanest�etized mice were placed and fixed in specially       
designed Perspex boxes�� isolated from t�e air�� and t�e   
normal tissue around t�e tumor was s�ielded as muc� 
as possible by placing some lead coverings upon t�e 
surface of t�e boxes. 
Measurement of tumor growth. Tumor size was 
measured wit� vernier calipers�� and tumor volume was 
calculated by t�e formula a × b�/� �a is t�e maximal dia-
meter�� b is t�e minimal diameter�� [1�]. T�e measure-
ment was performed daily after inoculation of tumor�� 
and weekly after radiation. Relative tumor volume was    
determined by taking t�e initial volume before radiation 
as 1. T�e time needed for a xenograft to reac� �-fold          
of its initial volume was defined as TGT�. Time of tumor 
growt� delay �TGD�� was t�e TGT� w�en compared wit� 
t�e control group�� e. g. TGD of RT group compared wit� 
untreated group�� TGD of RT + ATO group compared wit� 
RT alone group. 
Detection of toxic effect. In all experiments�� 
mice were monitored daily for signs of toxicity. On 
t�e ��t� week after radiation�� w�en t�e relative volume 
of tumor in eac� group reac�ed � times of t�e initial 
volume�� t�e mice were sacrificed. T�en t�e blood sam-
ples were collected. Examination of serum aspartate 
aminotransferase �AST�� and alanine aminotransferase 
�ALT�� levels were performed using an automated bio-
c�emistry mac�ine �Olympus�� Japan�� for evaluation of 
t�e toxic effects on liver function. After mice were sac-
rificed�� t�e toxic effects of t�erapy on t�e state of �eart�� 
lungs�� liver�� kidneys were detected �istologically.
Additional 1� mice were treated using t�e same 
regimen as in t�e group treated wit� ATO alone to 
evaluate t�e acute toxic effects. 
Statistical analysis. T�e results of TGD�� AST�� and 
ALT analyses were expressed as t�e mean ± standard 
deviation. T�e Student’s t-test was used to determine 
t�e significance of t�e differences among t�e treated 
groups compared wit� controls. A p- value of < �.�� 
was considered statistically significant.
RESULTS
Tumor response to the combined treatment of 
ATO and radiation. On t�e 1�t� day after t�e implanta-
tion of nasop�aryngeal carcinoma xenograft in mice�� 
��% of tumors were palpable �> � mm in lengt� diame-
ter��. On t�e �t� week after radiation t�erapy�� or t�e 
�3t� day after tumor implantation�� tumors in eac� group 
grew more t�an �-fold compared wit� t�at before ra-
diation. T�ere was no obvious c�ange in weig�t�� signs 
of life�� activity among various treatment groups.
T�e TGT�’s in t�e ATO alone group and t�e untreated 
group were �.� ± �.�� and �.� ± �.�� days�� respectively 
�p = �.������ indicating t�at ATO treatment alone �ad no 
impact on tumor growt�. In addition�� at t�e dose used 
in t�e present study�� ATO �ad no �ost toxicity�� t�erefore 
considering t�is dose as a non-toxic dose. However�� 
compared wit� t�at of RT alone group�� t�e tumor 
growt� delay by radiation was significantly en�anced 
by ATO in a dose-dependent manner w�en combined 
wit� t�e non-toxic doses of ATO. As s�own in Table 1�� 
w�en t�e relative tumor volume reac�ed ��� t�e tumor 
growt� delay from t�e combined treatment wit� ATO 
and RT was estimated to be about � �� Gy���� 13 �� Gy���� 
and �1 days �6 Gy���� respectively�� after t�e effects of 
ATO were deducted from t�e results�� significantly 
greater t�an t�at from RT alone �p < �.���� �Figure��. 
Table 1�� Tumor growth delay in experimental animals treated by RT alone 
and combined treatment with ATO and RT
RT dose Tumor growth delay (days)RT alone ATO + RT p value
2 Gy 1.9 ± 0.6 3.9 ± 1.3 < 0.05
4 Gy 7.6 ± 1.8 13 ± 2.4 < 0.05
6 Gy 11.9 ± 2.9 21.7 ± 4.4 < 0.05
Figure. T�e effects of combined treatment wit� ATO and radiation 
on nasop�aryngeal carcinoma xenografts in BALB/C nude mice
Evaluation of AST and ALT. No significant diffe-
rences in t�e levels of AST and ALT between control 
group and group wit� combined treatment by RT and ATO 
were observed �p > �.������ suggesting t�at t�e combined 
treatment was well tolerated in t�e experimental animals 
�Table ���.
Table 2�� AST and ALT levels in untreated group of animals and combined 
treatment group
Groups Results of liver function test AST U/L ALT U/L
Untreated
RT + ATO (2 Gy)
RT + ATO (4 Gy)
RT + ATO (6 Gy)
Control for toxic effect
40.1 ± 24.8
37.8 ± 32.4
37.3 ± 34.3
41.3 ± 35.1
47.3 ± 21.4
196.3 ± 45.6
174.7 ± 49.7
169.5 ± 52.3
178.2 ± 40.2
201.2 ± 25.5
There are no significant difference between the treated group and untreated 
group (p > 0.5).
�oreover�� no obvious toxic c�anges were found �is-
tologically in liver�� lung�� kidney�� and �eart tissue�� and no 
metastases were not found as well. T�ere were no differ-
ences in t�e toxicity among various treatment groups.
DISCUSSION 
Some recent studies �ave indicated t�at ATO mig�t 
en�ance radiation response in some solid tumors 
[���11�� 16]�� and t�e combined treatment wit� ATO and 
fractionated radiot�erapy are effective in t�e treat-
ment of relapsed acute promyelocytic leukemia [1��]�� 
but t�ere are no in vivo data supporting its effect in 
nasop�aryngeal carcinoma.
Hig� dose of radiation alone or ATO alone was 
required to treat nasop�aryngeal carcinoma effec-
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tively�� but some pat�ological c�anges in liver and 
cardiac tissues were found [1�]. In t�e current study�� 
TGT� was used to determine t�e treatment effect�� t�us�� 
t�e radiation doses used in t�e current study s�ould 
 enable all t�e xenografts to reac� � times of t�eir initial 
volumes and s�ould not cause tumor disappearance 
after irradiation. T�at is w�y we c�ose relatively low 
radiation doses �� Gy�� � Gy�� 6 Gy�� for t�e experiment. 
Before t�e drug administration�� we performed several 
preliminary experiments to determine t�e dose of 
ATO. T�ree doses ���� ���� and 1� mg/kg�� were used�� 
t�e ATO doses at �� and 1� mg/kg could lead to severe 
toxicity including deat�. In contrast�� no mice died at 
t�e dose of � mg/kg�� indicating t�at low dose of ATO 
caused less toxic effects. �oreover�� ATO alone at t�e 
dose of � mg/kg �ad no pronounced antitumor ef-
fect compared wit� t�e untreated controls. T�erefore 
t�e combination treatment wit� low dose of ATO may 
�ave clinical implication. Our results s�owed t�at t�e 
combined treatment wit� ATO and radiation delayed 
tumor growt� significantly�� suggesting t�e synergistic 
effects between ATO and radiation.
To determine t�e time for tumor growt� delay w�en 
t�e relative tumor volume reac�ed � times of t�e initial 
tumor size�� t�e data for ATO alone as control was de-
ducted�� t�us t�e in�ibitory effect of tumor growt� by 
combined ATO and RT s�owed t�e synergistic effects. 
As s�own in Table 1�� TGD of ATO combined wit� RT was 
�ig�er t�an t�at of RT alone�� w�ic� was dependent on 
t�e dose of radiation. T�ese results �ave demonstrated 
en�ancement of radiation response by ATO in naso-
p�aryngeal carcinoma in vivo�� and furt�er confirmed 
our previous results in vitro [13].
Considering t�at liver disfunction is a major adverse 
event of ATO in clinical treatment of leukemia [1�]�� we 
investigated t�e effects of combined treatment wit� ATO 
and RT on t�e level of AST and ALT in mice. To our knowl-
edge�� t�is is t�e first report on toxic effects of ATO on 
liver function in solid tumor models. We used two groups 
of animals for combined treatment�� one was sacrificed 
s�ortly after t�e last time of drug administration�� anot�er 
one was sacrificed by t�e end of t�e experiments. No 
significant difference in t�e levels of AST and ALT was 
found among t�e two groups and t�e untreated group�� 
indicating t�at no obvious liver disfunction was caused 
by t�e combined treatment. �oreover�� no significant 
toxic effects eit�er by observation of activity�� weig�t or 
pat�ological morp�ology�� indicating t�e combination 
wit� ATO and RT was a well tolerable treatment. 
In conclusion�� low dose of ATO en�ances t�e 
response of nasop�aryngeal carcinoma to radia-
tion t�erapy in nude mouse xenograft models w�ic� 
provides a basis for future studies wit� t�is combined 
regimen in patients wit� nasop�aryngeal carcinoma 
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СИНЕРГИЧНЫЙ� �ЕР��Е��ИЧЕС�ИЙ� ���Е�� �РИ��СИ��    
МЫШЬЯ�� И Р��И��ЕР��ИИ �� МЫШЕЙ� �ИНИИ BALB/C       
С �СЕН�ГР����МИ ��Р�ИН�МЫ Н�С�Г����И    
Установлено, что триоксид мышьяка (ТОМ) индуцирует апоптоз в клетках карциномы носоглотки человека и ингибирует 
рост ксенографта карциномы носоглотки у атимических мышей. Цель работы — установить терапевтическую эффектив-
ность радиотерапии в комбинации ТОМ в нетоксичной дозе мышам линии BALB/C с ксенографтом карциномы носоглотки.     
Методы: животные с ксенографтом карциномы носоглотки получали либо только радиотерапию (2, 4 и 6 Гр) или ТОМ 
(4 мг/кг/день в течение 6 дней), или их комбинацию в тех же режимах и дозах. �адержку роста опухоли определяли как                  
различие во времени, необходимом для достижения опухолью 4-кратного объема по сравнению с начальным объемом в 
опытной группе versus такового в контрольной группе. Результаты: введение ТОМ в низкой дозе не оказывало выраженного 
влияния на рост опухоли по сравнению с показателями в контрольной группе, а в комбинации с облучением приводило 
к задержке роста опухоли на 2–12 сут по сравнению с показателями у животных, получавших только лучевую терапию 
при отсутствии выраженных побочных эффектов. Выводы: комбинация ТОМ в нетоксической дозе и лучевой терапии 
приводит к ингибированию роста опухоли in vivo  и не вызывает побочных эффектов.
Ключевые слова: триоксид мышьяка, радиотерапия, ксенографт карциномы носоглотки.
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